Ted A Skolarus, Sarah T Hawley, Jane Forman, Anne E Sales, Jordan B Sparks, Tabitha Metreger, Jennifer Burns, Megan V Caram, Archana Radhakrishnan, Lesly A Dossett, Danil V Makarov, John T Leppert, Jeremy B Shelton, Kristian D Stensland, Jennifer Dunsmore, Steven Maclennan, Sameer Saini, Brent K Hollenbeck, Vahakn Shahinian, Daniela A Wittmann, Varad Deolankar, S Sriram
BACKGROUND: Many men with prostate cancer will be exposed to androgen deprivation therapy (ADT). While evidence-based ADT use is common, ADT is also used in cases with no or limited evidence resulting in more harm than benefit, i.e., overuse. Since there are risks of ADT (e.g., diabetes, osteoporosis), it is important to understand the behaviors facilitating overuse to inform de-implementation strategies. For these reasons, we conducted a theory-informed survey study, including a discrete choice experiment (DCE), to better understand ADT overuse and provider preferences for mitigating overuse...
April 9, 2024: Implementation science communications